Search
Utah Paid Clinical Trials
A listing of 1240 clinical trials in Utah actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 1240
Utah is currently home to 1240 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Cardiovascular Disease Trials
Recruiting
Cardiovascular Disease trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Cardiovascular Disease
Featured Trial
Overweight Trials
Recruiting
Overweight trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Overweight
Featured Trial
Low back pain Trials
Recruiting
Low back pain trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Low back pain
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Jordan Valley Dermatology Center, West Jordan, Utah
Conditions: NonSegmental Vitiligo
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Participants With Influenza
Recruiting
The purpose of this study is to evaluate the pre-treatment and single-dose post treatment susceptibility of baloxavir marboxil in participants aged 1 to <12 years with influenza.
Gender:
All
Ages:
Between 1 year and 11 years
Trial Updated:
06/21/2024
Locations: Velocity Clinical Research, Salt Lake City, West Jordan, Utah
Conditions: Influenza
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Recruiting
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Modified Mayo Sc... Read More
Gender:
All
Ages:
Between 16 years and 75 years
Trial Updated:
06/21/2024
Locations: Velocity Clinical Research, Salt Lake City ( Site 3801), West Jordan, Utah
Conditions: Ulcerative Colitis
Strategy for Improving Stroke Treatment Response
Recruiting
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: University of Utah Healthcare, Salt Lake City, Utah
Conditions: Ischemic Stroke
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Recruiting
This phase I/II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started to other places in the body (metastatic) in kidney transplant recipients. Immunotherapy with nivolumab and ipilimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Sirolimus and prednisone... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Carcinoma in the Skin, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Recruiting
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT) gliomas with FGFR-TACC gene fusion that have returned or that have grown, spread, or gotten worse (progressed). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals tumor cells to multiply. This may help keep tumor cells from growing and may kill them. Giving erdafitinib may help to slow the growth of or to shrink tumor cell... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Recruiting
This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form... Read More
Gender:
All
Ages:
Between 180 days and 22 years
Trial Updated:
06/21/2024
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
Recruiting
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: The University of Utah - Huntsman Mental Health Institute, Salt Lake City, Utah
Conditions: Treatment Resistant Depression
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Recruiting
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 posi... Read More
Gender:
All
Ages:
Between 5 years and 60 years
Trial Updated:
06/21/2024
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
Recruiting
Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Cedar Clinical Research, Draper, Utah
Conditions: Treatment Resistant Depression
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
Recruiting
This phase II trial tests whether adding nivolumab to the usual treatment (encorafenib and cetuximab) works better than the usual treatment alone to shrink tumors in patients with colorectal cancer that has spread to other places in the body (metastatic) or that cannot be removed by surgery (unresectable) and whose tumor has a mutation in a gene called BRAF. Encorafenib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Recruiting
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 recept... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Endometrial Serous Adenocarcinoma, Uterine Corpus Carcinosarcoma